Peijia Medical: Expected revenue of approximately 700 million to 720 million yuan in 2025, representing a year-over-year growth of about 13.7-17.0%

2026-02-26 08:12:48

Peijia Medical announces that its expected revenue in 2025 will be approximately 700 million to 7.2 billion yuan, representing a year-over-year growth of about 13.7% to 17.0%. The group’s sustained revenue growth is mainly attributed to: (i) the strong performance of all three major product lines in the neurointervention business; and (ii) the continuous expansion of market share in China’s transcatheter aortic valve replacement (TAVR) market, primarily driven by the successful launch of the high-end TaurusMax 3D adjustable curved TAVR system.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.